Securities and Exchange Commission, Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

(Name of Issuer)

Praxis Precision Medicines, Inc.

(Title of Class of Securities)

Common Stock, par value $0.0001 per share

(CUSIP Number)

74006W108

(Date of Event Which Requires Filing of this Statement)

[  ] Rule 13d-1(b)

[ x ] Rule 13d-1(c)

[  ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see
the Notes).

Item 1(a) Name of issuer:

Praxis Precision Medicines, Inc.

Item 1(b) Address of issuer's principal executive offices:

99 High Street, 30^th Floor, Boston, MA 02110

2(a) Name of persons filing (the “Reporting Persons”):

This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”)
with respect to 100,000 shares of common stock, par value $0.0001 per share (“Common
Stock”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc.
(“Point72 Capital Advisors Inc.”) with respect to shares of Common Stock held by an investment
fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist
Systematic Strategies”) with respect to 17,920 shares of Common Stock held by an investment
fund it manages; (iv) Point72 Middle East FZE (“Point72 Middle East”) with respect to 2,269
shares of Common Stock held by an investment fund it manages; (v) Point72 Biotech Private
Investments, LLC (“Point72 Biotech”) with respect to 988,995 shares of Common Stock of
which it is the holder; (vi) Differentiated Ventures Investments, LLC (“Differentiated
Ventures”), the managing member of Point72 Biotech, with respect to the shares of Common
Stock held by Point72 Biotech; (vii) 72 Investment Holdings, LLC (“72 Investment Holdings”),
the sole member of Differentiated Ventures, with respect to the shares of Common Stock held by
Point72 Biotech, and (viii) Steven A. Cohen (“Mr. Cohen”) the sole member of 72 Investment
Holdings and sole shareholder of Point72 Capital Advisors Inc., with respect to: (A) the 100,000
shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital
Advisors Inc., (B) the 17,920 shares of Common Stock beneficially owned by Cubist System
Strategies, (C) the 2,269 shares of Common Stock beneficially owned by Point72 Middle East
and (D) the 988,995 shares of Common Stock beneficially owned Point72 Biotech,
Differentiated Ventures, and 72 Investment Holdings.

Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72
Hong Kong, Point72 Middle East, Point72 Biotech, Differentiated Investors, 72 Investment
Holdings, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed
with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule
13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

2(b) Address or principal business office or, if none, residence:

The address of the principal business office of (i) Point72 Asset Management, Point72 Capital
Advisors Inc., Point72 Biotech, Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen
is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson
Yards, New York, NY 10001; (iii) Point72 Hong Kong is Suites 1102 -1110, 11th Floor and 12th
Floor, Chater House, 8 Connaught Road Central, Hong Kong; and (iv) Point72 Middle East is
EO3, 04, Sheikh Rashid Tower, Dubai World Trade Centre, Dubai, United Arab Emirates.

2(c) Citizenship:

Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
Delaware corporation. Cubist Systematic Strategies, Point72 Biotech, Differentiated Ventures,
and 72 Investment Holdings are Delaware limited liability companies. Point72 Hong Kong is a
Hong Kong limited liability company. Point72 Middle East is a limited liability free zone
establishment.   Mr. Cohen is a United States citizen.

2(d) Title of class of securities:

Common Stock, par value $0.0001 per share

2(e) CUSIP Number:

74006W108

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Such information is as of the close of business on December 31, 2022.

Point72 Asset Management is the manager to a private investment fund that is the holder of
100,000 shares of Common Stock.  Pursuant to an investment management agreement, Point72
Asset Management maintains investment and voting power with respect to securities held by
such private investment fund and, as a result, may be deemed to share beneficial ownership over
the 100,000 shares of Common Stock held by such fund.  Point72 Capital Advisors, Inc. is the
general partner of Point72 Asset Management and may be deemed to share beneficial ownership
of the shares of Common Stock of which Point72 Asset Management may be deemed the
beneficial owner.

Cubist Systematic Strategies is the manager to a private investment fund that is the holder of
17,920 shares of Common Stock.   Pursuant to an investment management agreement, Cubist
Systematic Strategies maintains investment and voting power with respect to securities held by
such private investment fund and, as a result, may be deemed to share beneficial ownership over
the 17,920 shares of Common Stock held by such fund.

Point72 Middle East is the manager to a private investment fund that is the holder of 2,269
shares of Common Stock.   Pursuant to an investment management agreement, Point72 Middle
East maintains investment and voting power with respect to securities held by such private
investment fund and, as a result, may be deemed to share beneficial ownership over the 2,269
shares of Common Stock held by such fund.

Point72 Biotech is the holder of 988,995 shares of Common Stock.  Differentiated Ventures is
the managing member of Point72 Biotech and may be deemed to share beneficial ownership over
the shares of Common Stock held by Point72 Biotech.  72 Investment Holdings is the sole
member of Differentiated Ventures and may be deemed to share beneficial ownership of the
shares of Common Stock of which Differentiated Ventures may be deemed the beneficial owner.

Mr. Cohen is the sole member of 72 Investment Holdings and sole shareholder of Point72
Capital Advisors Inc. and may be deemed to beneficially own both the 988,995 shares of
Common Stock of which 72 Investment Holdings may be deemed the beneficial owner and the
100,000 shares of Common Stock of which Point72 Capital Advisors Inc. may be deemed the
beneficial owner.

The filing of this statement should not be construed as an admission that any of the foregoing
persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial
owner of the Common Stock reported herein.

Not applicable

Item 8. Identification and Classification of Members of the Group

Dated: February 14, 2023

Dated: February 14, 2023

By: /s/ Jason M. Colombo
Name: Jason M. Colombo
Title: Authorized Person